Batu Biologics batubiologics.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Batu Biologics is a biopharmaceutical company based in San Diego seeking to translate cell and gene therapies for the treatment of cancer. Batu is focused on developing the "ValloVax" platform, an allogeneic and universal donor cellular vaccine designed to stimulate a targeted immune response against the blood vessels of the tumor for a wide array of cancers.

Batu Biologics is a biopharmaceutical company based in San Diego seeking to translate cell and gene therapies for the treatment of cancer. Batu is focused on developing the "ValloVax" platform, an allogeneic and universal donor cellular vaccine desig...Show all

Company (Alive / Active)

All investors data 4 Investors

Phone: 213-359-3179

Fax:

9255 Towne Centre Dr
Suite 450
 San Diego, 92121
 California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Batu Biologics $2.9M Dec 26, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Batu Biologics Jobs

jobs by Indeed job search

Investors

Investor Investor Type Location Participating Rounds
See all 4 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Use of antioxidants as an adjuvant to immune stimulators to augment tumor immunity and prevent toxicity associated with oxidative stress May 07, 2015 Jun 27, 2017 Patent
Immunotherapy of cancer by induction of immunologically-mediated selective killing of tumor vasculature using modified endothelial cells and progenitors thereof Oct 20, 2017 Application
Chimeric antigen receptor targeting of tumor endothelium Sep 22, 2017 Application
Adjuvants useful for stimulation of immunity to tumor endothelial cells Jun 01, 2017 Application
Probiotic augmentation of anti-tumor endothelium immune responses Jun 01, 2017 Application
See all 24 patents